"Pharmaceutical Speed Reader" Considine won the IPO approval of The Board of Science and Technology Shanghai Leith pre-increasenet net profit of more than 60%.

July 16, 2020 / Medical Information List: Consino was approved by Co-founder sitcoms, Novocure reached a cooperation agreement with Mercado, Fosun Pharma's new coronavirus mRNA vaccine Phase I clinical trial was approved, the first type 1 liver and kidney syndrome (HRS-1) drug was approved by the FDA, and Shanghai Leishi pre-added more than 60% net profit... Daily fresh medicine to hear medical news, fast-reading society with you to pay attention! Part 1 Policy Briefing State Drug Administration: A number of well-known arms enterpriseproducts were approved recently, the official website of the State Drug Administration issued the "State Drug Administration on the approval of the registration of 107 medical device products announcement (2020 No. 83)."
announcement shows that in June 2020, the State Drug Administration approved a total of 107 registered medical device products.
, 59 domestic medical device products, 24 imports of third-class medical device products, 24 imports of second-class medical device products.
this approved device sits in Medtronice, Philips, Siemens, Abbott, GE, Roche Diagnostics, Stryker, Murray, Lepu, Syngenta, Neusoft, Shandong Xinhua and other equipment products.
(National Drug Administration) "Static injection of human immunoglobulin treatment of primary immunoglomathroma clinical trial technical guidelines (draft for comments)" published on the 16th, CDE publicly solicited the "static injection of human immunoglobulin treatment of primary immunoplatelet disease clinical trial technical guidelines (draft for comments)" comments, with a view to drug research and development registration applicants and drug clinical trials to provide more targeted advice and guidelines.
(CDE) next month clinics to implement new regulations on medical insurance supervision 19 red lines don't touch Suzhou City Medical Insurance Bureau and the City Credit Office jointly formulated the "Suzhou Fixed-point outpatient department, clinic medical security credit rating evaluation management measures (trial)", will implement the clinic credit rating dynamic management, divided into excellent, medium, good, poor four grades, for different credit ratings have different incentives and supervision.
(Suzhou Municipal Medical Insurance Bureau) Medical Insurance Bureau announced: check the drug companies, carry out drug cost investigation days ago, Heilongjiang Medical Insurance Bureau issued the "drug and medical supplies centralized procurement and price supervision and inspection measures (trial)," according to combing, the Heilongjiang identified administrative law enforcement matters related to drug price monitoring, drug cost investigation, standardized drug collection, drug price recruitment credit evaluation system.
(Heilongjiang Medical Insurance Bureau) Part 2 production observed that Consino was approved by the IPO of the first A-H vaccine shares on the 15th, the CSRC issued a number of enterprises, including The Company's IPO approval, including Considine Bio.
this means that Consino Bio, which has attracted much attention for the development of the new crown vaccine, will become the first A-share "A-H" vaccine unit.
(CSRC) Shanghai Laishi: 2020 first half of the pre-increase net profit of 695 million to 745 million recently, Shanghai Leishi issued a first-half 2020 earnings forecast, expected the first half of 2020 attributable to shareholders of listed companies net profit of 695 to 745 million yuan, an increase of 68% to 80% YoY. The main reason for the
is that Shanghai Laishi completed the transfer of 45% of the GDS shares under the target of a major asset restructuring on March 25, 2020, and enjoyed the return on investment income calculated at 45% of the investment ratio since the transfer of GDS equity.
(Shanghai Leith Announcement) Novocure and Mercadon have reached a cooperation agreement for the treatment of non-small cell lung cancer patients Novocure announced that it has reached a clinical trial cooperation agreement with Mercado, under which Novocure and Mercadon plan to conduct a Phase 2 clinical pilot study to combine the tumor treatment electric field with Mercadon's heavy anti-PD-1 therapy Keytruda to treat patients with non-small cell lung cancer.
(Pharmaceutical MingKang) Yan Yuan Pharmaceuticals and South Korea's NewG Lab co-development of ROS1/NTRK dual-target inhibitors 16, Yu Yuan Pharmaceuticals announced that the company has reached a partnership with NewG Lab Pharma in South Korea, its next generation ROS1 /NTRK inhibitortaletctinib in the Korean market clinical development and commercialization interests exclusively awarded to the latter.
(Pharmaceutical Mission) Part 3 Pharmaceutical Information Alzheimer's Disease Innovation Therapy Clinical Results Positively Reduce Neuroinflammation in Important Brain Tissues 40%, INmune Bio announced that its main candidate drug XPro1595, in Phase 1b clinical trials, significantly reduce sedituated nerve inflammation in Alzheimer's patients.
XPro1595 is a new generation of inhibitors of tumor necrosis, selectively neutralising the function of soluble TNF without affecting transmembrane TNF or TNF receptors.
(Drug Mingkang) Cardoso Double Anti-Gastric Cancer International Multi-Center Clinical Trials will open the world's first T cell cell engaged bispecific antibody drug Cartoso recently obtained nMPA, MOHW and MFDS clinical trial approval for the expansion of gastric cancer indications, opening a new clinical journey.
(PharmaRubikt) Hengrui PharmaceuticalSHsiewith SHR-1703 Injection shrivelled drug clinical trial approval notice 15, Hengrui Pharmaceuticals issued a notice that the company recently received the State Drug Administration approved the issuance of the SHR-1703 injection of the "drug clinical trial approval notice", and will be launched in the near future clinical trials.
(Hengrui Pharmaceutical announcement) Fosun Pharma's new coronavirus mRNA vaccine Phase I clinical trial was approved by Star Pharma announced that the company's holding subsidiary Shanghai Fosun Pharma recently received approval from the State Drug Administration for its licensed new coronavirus mRNA vaccine (BNT162b1) for the prevention of new coronavirus pneumonia clinical trials.
Fosun Pharma intends to conduct Phase I clinical trials of the vaccine in China (excluding Hong Kong, Macao and Taiwan) when the conditions are met.
(Sina Pharmaceutical News) Qilu Pharmaceutical 4 generic drug Aripitin was approved in the recent Qilu Pharmaceutical 4 generic arigitan capsule listing application (acceptance number CYHS1800538, 539) in the NMPA status change dating "in approval", which means that the first domestic Arigitan capsule was approved in the immediate.
(CPhI Pharmaceuticals Online) Dongsun Pharmaceuticals' Fumasic sic acid thiopine 4 class generic listing application was accepted CDE official website shows that Guangdong East Sunshine Pharmaceuticals Fuma sic acid thiopine 4 class generic listing application was accepted.
fumatosic thiopines is a non-classical antipsychotic drug used to treat schizophrenia and the manic episode of bipolar disorder.
(CDE) Bollinger Ingerheim nintedanib has been approved by the European Union for the third indications Ofev (nintedanib, Nidanib) anti-pulmonary fibrosis treatment drug Ofev (nintedanib) has been approved by the European Union for the treatment of ispecialpulmonary fibrosis outside of the developed phenotype asexual interstitial pulmonary disease (PF-ILD) adult patients.
(Sina Pharmaceutical News) Dirui Medical 2 medical device products by the European Union CE certification 16, Dirui Medical issued a notice that the company's 2 medical device products (probe conditioning fluid, urine sample collector) recently obtained CE certification, this product involves the IVD industry chemical luminescent immunoassay analysis, biochemical diagnostic analysis and urine analysis field.
(Dire Medical Bulletin) the first type 1 hepatic and kidney syndrome (HRS-1) drug was recommended by the FDA panel of experts approved on the 15th, Mallinckrodt announced that the FDA Advisory Committee on Cardiovascular and Kidney Medicines voted (8 in favor vs 7 against) to recommend approval of its research drug terlipressin for the treatment of liver and kidney syndrome type 1 (HRS-1) adults.
(Sina Pharmaceutical News) ASHENG PharmaceuticalSa Bcl-2 inhibitor APG-2575 for the treatment of WM was certified by the FDA Orphan Drug on the 15th, AXA Pharmaceuticals announced that the U.S. FDA has awarded its Bcl-2 inhibitor APG-2575 orphan drug eligibility for the treatment of Fahrenheit polycylobinemia (WM).
this is the first orphan drug qualification obtained by APG-2575, and the second orphan drug qualification from the FDA.
(Pharmaceutical Rubik's Cube) Lumasiran UK has been approved to treat the underlying cause of primary hypergraminiemia type 1, the UK Medicines and Health Products Agency has issued a positive scientific opinion on Lumasiran's early access to drugs.
the decision, eligible patients with leukuric acid type 1 in the UK, many of them children, will be able to access the treatment before lumasiran is approved by the European Commission.
(Bio Valley)